The pathogenesis of drug‐induced gingival overgrowth
RA Seymour, JM Thomason… - Journal of clinical …, 1996 - Wiley Online Library
Gingival overgrowth is a well‐documented unwanted effect, associated with phenytoin,
cyclosporin. and the calcium channel blockers. The pathogenesis of drug‐induced gingival …
cyclosporin. and the calcium channel blockers. The pathogenesis of drug‐induced gingival …
Drug-induced gingival overgrowth—a review
M Kataoka, J Kido, Y Shinohara… - Biological and …, 2005 - jstage.jst.go.jp
Drug-induced gingival overgrowth is a side effect associated with 3 types of drugs:
anticonvulsants (phenytoin), immunosuppressive agents (cyclosporine A), and various …
anticonvulsants (phenytoin), immunosuppressive agents (cyclosporine A), and various …
Gingival enlargement induced by drugs
L Brunet, J Miranda, M Farré, L Berini, C Mendieta - Drug Safety, 1996 - Springer
Gingival enlargement, an abnormal growth of the periodontal tissue, is mainly associated
with dental plaque-related inflammation and drug therapy. Its true incidence in the general …
with dental plaque-related inflammation and drug therapy. Its true incidence in the general …
Medically induced gingival hyperplasia
SJ Meraw, PJ Sheridan - Mayo Clinic Proceedings, 1998 - Elsevier
Gingival hyperplasia or gingival overgrowth is a common occurrence in patients taking
phenytoin, cyclosporine, or calcium channel blockers. Speech, mastication, tooth eruption …
phenytoin, cyclosporine, or calcium channel blockers. Speech, mastication, tooth eruption …
[PDF][PDF] Treatment of drug-induced gingival enlargement: aesthetic and functional considerations.
PM Camargo, PR Melnick, FQM Pirih, R Lagos… - Periodontology …, 2001 - academia.edu
Gingival enlargement is one of the side effects associated with the administration of several
drugs. These drugs can be basically divided into three groups: anticonvulsants, calcium …
drugs. These drugs can be basically divided into three groups: anticonvulsants, calcium …
Prevalence and risk of gingival enlargement in patients treated with nifedipine
J Miranda, L Brunet, P Roset, L Berini… - Journal of …, 2001 - Wiley Online Library
Background: Gingival enlargement is a known side effect of nifedipine use. This study was
conducted to determine the prevalence and risk factors for gingival enlargement in …
conducted to determine the prevalence and risk factors for gingival enlargement in …
Oral adverse drug reactions to cardiovascular drugs
LA Torpet, C Kragelund, J Reibel… - Critical reviews in oral …, 2004 - journals.sagepub.com
A great many cardiovascular drugs (CVDs) have the potential to induce adverse reactions in
the mouth. The prevalence of such reactions is not known, however, since many are …
the mouth. The prevalence of such reactions is not known, however, since many are …
Prevalence and risk of gingival enlargement in patients treated with anticonvulsant drugs
L Brunet, J Miranda, P Roset, L Berini… - European journal of …, 2001 - Wiley Online Library
Background Predictors of gingival enlargement in patients treated with anti‐epileptics have
not been previously assessed. This study was conducted to determine, with the aid of two …
not been previously assessed. This study was conducted to determine, with the aid of two …
Gingival enlargement in children treated with antiepileptics
H Tan, T Gürbüz, IM Dağsuyu - Journal of child neurology, 2004 - journals.sagepub.com
This study was conducted to determine the occurrence, severity, and risk factors of gingival
enlargement in children treated with valproate and other nonvalproate antiepileptic drugs. A …
enlargement in children treated with valproate and other nonvalproate antiepileptic drugs. A …
Evaluation of the frequency of HLA determinants in patients with gingival overgrowth induced by cyclosporine‐A
I Cebeci, A Kantarci, E Firatli, S Aygün… - Journal of clinical …, 1996 - Wiley Online Library
This study has been designed to investigate the immunogenetic susceptibility of
Cyclosporine‐A (CsA) immunosuppressed renal transplant patients to development of …
Cyclosporine‐A (CsA) immunosuppressed renal transplant patients to development of …